F10.2
Conditions
Interventions
Group 1: control group: alcohol picture exposure with attention control (without specific inhibition training), controlling for unspecific involvement of using a therapy-related app within the clinica
Sponsors
Universität Bern
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients: - Primary diagnosis of AUD (i.e. no psychotic, bipolar and personality disorder as primary diagnosis), - abstinence from alcohol for = 2 weeks prior to pre-training & plasticity assessment, or = 1 week after successful completion of detoxification - sufficient ability to read and understand German, - access to a smartphone where the Alc-IT can be installed. Additional inclusion criteria for patients in embedded EEG-study: - willingness to participate in EEG study HC: - willingness to participate in EEG study
Exclusion criteria
Exclusion criteria: Patients: - other severe substance use disorder (SUD) drug use identification test (DUDIT) = 25 per substance - diagnosed neurocognitive disorders (e.g., Korsakoff syndrome) - current medical conditions preventing participation (e.g., acute infectious diseases) - active benzodiazepine medication (i.e. daily use) - prior/active enrollment in an overlapping or competing study - the enrollment of a main investigator, their family members, employees and other dependent persons. Additional exclusion criteria for patients in embedded EEG-study: - cochlear implant - history of epilepsy - active pregabalin or benzodiazepine medication (i.e. 4 half-lives of medication) before EEG measurement HC: - cochlear implant - history of epilepsy - active pregabalin or benzodiazepine medication (i.e. 4 half-lives of medication) before EEG measurement - currently undergoing treatment for psychopathological symptoms or history of severe psychiatric diagnosis - problematic substance use (Alcohol Use Disorder identification test (AUDIT) =8 or DUDIT =2) - diagnosed neuronal or neurocognitive disorders - current medical conditions preventing participation (e.g., acute infectious diseases)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A) Drinking behaviour at 3-months follow-up (3mFU) from percentage of days abstinent (PDA) B) Neurophysiology of alcohol-specific inhibition from Alcohol-related NoGo-P300 at post-training assessment | — |
Secondary
| Measure | Time frame |
|---|---|
| A1) Modulation of visual event-related potential (VEPm) as indicator for plasticity A2) PDA (hypothesized to be moderated by VEPm) A3) life satisfaction at discharge (hypothesized to be moderated by VEPm) B1) PDA at 3mFU (hypothesized to be moderated by alcohol-related NoGo-P300) C1) PDA at entry and C2) PDA at 3mFU (related to emotional processing (via mixed-methods)) | — |
Countries
Switzerland
Contacts
Public ContactMaria Stein
Universität Bern
Outcome results
None listed